A Phase 3b/4,Multi-center, Double-blind, Randomized, Parallel Group Study Of Tofacitinib (Cp-690,550) In Subjects With Ulcerative Colitis In Stable Remission

Trial Profile

A Phase 3b/4,Multi-center, Double-blind, Randomized, Parallel Group Study Of Tofacitinib (Cp-690,550) In Subjects With Ulcerative Colitis In Stable Remission

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms RIVETING STUDY
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 07 Nov 2017 Planned End Date changed from 14 Dec 2019 to 1 Dec 2021.
    • 15 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top